Our computational analysis identifies the miR-34a-5p/CDH1 axis as a novel regulatory mechanism in prostate adenocarcinoma, highlighting its potential as a biomarker and therapeutic target for EMT inhibition. The gene discussed is CDH1; the disease is prostate adenocarcinoma.